• 1
    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al.International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).J Thromb Haemost2006;4:295306.
  • 2
    Cucurull E, Gharavi AE, Diri E, Mendez E, Kapoor D, Espinoza LR.IgA anticardiolipin and anti-β2-glycoprotein I are the most prevalent isotypes in African American patients with systemic lupus erythematosus.Am J Med Sci1999;318:5560.
  • 3
    Pierangeli SS, Liu SW, Anderson G, Barker JH, Harris EN.Thrombogenic properties of murine anti-cardiolipin antibodies induced by β2 glycoprotein 1 and human immunoglobulin G antiphospholipid antibodies.Circulation1996;94:174651.
  • 4
    Diri E, Cucurull E, Gharavi AE, Kapoor D, Mendez EA, Scopelitis E, et al.Antiphospholipid (Hughes') syndrome in African-Americans: IgA aCL and anti-β2 glycoprotein-I is the most frequent isotype.Lupus1999;8:2638.
  • 5
    Bertolaccini ML, Atsumi T, Escudero Contreras A, Khamashta MA, Hughes GR.The value of IgA antiphospholipid testing for diagnosis of antiphospholipid (Hughes) syndrome in systemic lupus erythematosus.J Rheumatol2001;28:263743.
  • 6
    Danowski A, Kickler TS, Petri M.Anti-β2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus.J Rheumatol2006;33:17759.
  • 7
    Fanopoulos D, Teodorescu MR, Varga J, Teodorescu M.High frequency of abnormal levels of IgA anti-β2-glycoprotein I antibodies in patients with systemic lupus erythematosus: relationship with antiphospholipid syndrome.J Rheumatol1998;25:67580.
  • 8
    Mehrani T, Petri M.Association of IgA anti-β2 glycoprotein I with clinical and laboratory manifestations of systemic lupus erythematosus.J Rheumatol2011;38:648.
  • 9
    Iverson GM, von Muhlen CA, Staub HL, Lassen AJ, Binder W, Norman GL.Patients with atherosclerotic syndrome, negative in anti-cardiolipin assays, make IgA autoantibodies that preferentially target domain 4 of β2-GPI.J Autoimmun2006;27:26671.
  • 10
    Martinez-Martinez LA, Aguilar-Valenzuela R, Seif A, Binder W, Alarcon G, Pierangeli S.Do clinically relevant IgA anti-β2glycoprotein I (anti-β2GPI) antibodies bind to DIV/V of β2GPI? [abstract].Lupus2010:19:C130.
  • 11
    Kumar S, Papalardo E, Sunkureddi P, Najam S, González EB, Pierangeli SS.Isolated elevation of IgA anti-β2glycoprotein I antibodies with manifestations of antiphospholipid syndrome: a case series of five patients.Lupus2009;18:10114.
  • 12
    Sweiss NJ, Bo R, Kapadia R, Manst D, Mahmood F, Adhikari T, et al.IgA anti-β2-glycoprotein I autoantibodies are associated with an increased risk of thromboembolic events in patients with systemic lupus erythematosus.PLoS One2010;5:e12280.
  • 13
    Gabeta S, Norman GL, Gatselis N, Liaskos C, Papamichalis PA, Garagounis A, et al.IgA anti-β2GPI antibodies in patients with autoimmune liver diseases.J Clin Immunol2008;28:50111.
  • 14
    Boin F, Franchini S, Colantuoni E, Rosen A, Wigley FM, Casciola-Rosen L.Independent association of anti–β2-glycoprotein I antibodies with macrovascular disease and mortality in scleroderma patients.Arthritis Rheum2009;60:24809.
  • 15
    Reveille JD, Moulds JM, Ahn C, Friedman AW, Baethge B, Roseman J, et al, for the LUMINA Study Group.Systemic lupus erythematosus in three ethnic groups. I. The effects of HLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset.Arthritis Rheum1998;41:116172.
  • 16
    Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al.The 1982 revised criteria for the classification of systemic lupus erythematosus.Arthritis Rheum1982;25:12717.
  • 17
    Pierangeli SS, Harris EN.A protocol for determination of anticardiolipin antibodies by ELISA.Nat Protoc2008;3:8408
  • 18
    Lee SS, Cho ML, Joo YS, Kim WU, Hong YS, Min JK, et al.Isotypes of anti-β2-glycoprotein I antibodies: association with thrombosis in patients with systemic lupus erythematosus.J Rheumatol2001;28:5204.
  • 19
    Lakos G, Kiss E, Regeczy N, Tarjan P, Soltesz P, Zeher M, et al.Isotype distribution and clinical relevance of anti-β2-glycoprotein I (β2-GPI) antibodies: importance of IgA isotype.Clin Exp Immunol1999;117:5749.
  • 20
    Staub HL, Franck M, Ranzolin A, Norman GL, Iverson GM, von Muhlen CA.IgA antibodies to β2-glycoprotein I and atherosclerosis.Autoimmun Rev2006;6:1046.
  • 21
    Ranzolin A, Bohn JM, Norman GL, Manenti E, Bodanese LC, von Muhlen CA, et al.Anti-β2-glycoprotein I antibodies as risk factors for acute myocardial infarction.Arq Bras Cardiol2004;83:1414.
  • 22
    Staub HL, Norman GL, Crowther T, da Cunha VR, Polanczyk A, Bohn JM, et al.Antibodies to the atherosclerotic plaque components β2-glycoprotein I and heat-shock proteins as risk factors for acute cerebral ischemia.Arq Neuropsiquiatr2003;61:75763.
  • 23
    Yamada H, Tsutsumi A, Ichikawa K, Kato EH, Koike T, Fujimoto S.IgA-class anti–β2-glycoprotein I in women with unexplained recurrent spontaneous abortion.Arthritis Rheum1999;42:27278.
  • 24
    Lee RM, Branch DW, Silver RM.Immunoglobulin A anti-β2-glycoprotein antibodies in women who experience unexplained recurrent spontaneous abortion and unexplained fetal death.Am J Obstet Gynecol2001;185:74853.
  • 25
    Shen YM, Lee R, Frenkel E, Sarode R.IgA antiphospholipid antibodies are an independent risk factor for thromboses.Lupus2008;17:9961003.
  • 26
    Pierangeli SS, Liu X, Espinola R, Olee T, Zhu M, Harris NE, et al.Functional analyses of patient-derived IgG monoclonal anticardiolipin antibodies using in vivo thrombosis and in vivo microcirculation models.Thromb Haemost2000;84:38895.
  • 27
    Pierangeli SS, Barker JH, Stikovac D, Ackerman D, Anderson G, Barquinero J, et al.Effect of human IgG antiphospholipid antibodies on an in vivo thrombosis model in mice.Thromb Haemost1994;71:6704.
  • 28
    Pierangeli SS, Liu X, Barker JH, Anderson G, Harris EN.Induction of thrombosis in a mouse model by IgG, IgM and IgA immunoglobulins from patients with the antiphospholipid syndrome.Thromb Haemost1995;74:13617.
  • 29
    Bertolaccini ML, Amengual O, Atsumi T, Binder WL, de Laat B, Forastiero R, et al.‘Non-criteria’ aPL tests: report of a task force and preconference workshop at the 13th International Congress on Antiphospholipid Antibodies, Galveston, TX, USA, April 2010.Lupus2011;2:191205.
  • 30
    Petri M, Orbai AM, Alarcon GS, Gordon C, Merrill JT, Fortin PR, et al.Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus.Arthritis Rheum2012;64:267786.